Blueshift Asset Management LLC Invests $174,000 in Kura Oncology, Inc. (NASDAQ:KURA)

Blueshift Asset Management LLC acquired a new position in shares of Kura Oncology, Inc. (NASDAQ:KURA) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 20,031 shares of the company’s stock, valued at approximately $174,000.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Point72 DIFC Ltd purchased a new position in shares of Kura Oncology during the third quarter worth $146,000. E Fund Management Co. Ltd. acquired a new position in Kura Oncology during the 4th quarter worth about $90,000. Erste Asset Management GmbH purchased a new position in Kura Oncology during the 3rd quarter valued at about $215,000. Corient Private Wealth LLC acquired a new position in Kura Oncology in the 4th quarter valued at about $109,000. Finally, Bellevue Group AG increased its stake in Kura Oncology by 36.0% during the third quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock worth $266,000 after purchasing an additional 3,600 shares during the period.

Insider Activity at Kura Oncology

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the transaction, the senior vice president now owns 88,193 shares of the company’s stock, valued at $694,078.91. The trade was a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Mollie Leoni sold 4,963 shares of the stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the sale, the insider now directly owns 88,253 shares of the company’s stock, valued at $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,729 shares of company stock valued at $92,307 over the last ninety days. Insiders own 5.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on KURA shares. Wedbush restated an “outperform” rating and issued a $36.00 price objective on shares of Kura Oncology in a report on Thursday, February 27th. Cantor Fitzgerald upgraded shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, March 4th. UBS Group reduced their price objective on Kura Oncology from $27.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. JMP Securities reissued a “market outperform” rating and set a $28.00 target price on shares of Kura Oncology in a research note on Thursday, February 6th. Finally, BTIG Research lowered Kura Oncology from a “buy” rating to a “neutral” rating in a research report on Thursday, February 6th. Four research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $25.50.

Kura Oncology Price Performance

Shares of NASDAQ KURA opened at $7.84 on Friday. The stock’s 50-day simple moving average is $7.82 and its 200-day simple moving average is $12.43. The firm has a market capitalization of $633.12 million, a PE ratio of -3.32 and a beta of 0.85. Kura Oncology, Inc. has a fifty-two week low of $6.79 and a fifty-two week high of $23.48. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.43. The company had revenue of $53.88 million for the quarter, compared to analysts’ expectations of $57.96 million. As a group, equities research analysts forecast that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.